Literature DB >> 34050876

Letter to the editor.

Fengli Wang1, Lujin Li2.   

Abstract

Year:  2021        PMID： 34050876     DOI： 10.1007/s11255-021-02898-4

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN： 0301-1623            Impact factor:   2.370


× No keyword cloud information.
  4 in total

1.  Vibegron, a Novel Potent and Selective β3-Adrenoreceptor Agonist, for the Treatment of Patients with Overactive Bladder: A Randomized, Double-blind, Placebo-controlled Phase 3 Study.

Authors:  Masaki Yoshida; Masayuki Takeda; Momokazu Gotoh; Shinji Nagai; Takafumi Kurose
Journal:  Eur Urol       Date:  2018-02-01       Impact factor: 20.096

2.  Long-term safety and efficacy of the novel β3 -adrenoreceptor agonist vibegron in Japanese patients with overactive bladder: A phase III prospective study.

Authors:  Masaki Yoshida; Hidehiro Kakizaki; Satoru Takahashi; Shinji Nagai; Takafumi Kurose
Journal:  Int J Urol       Date:  2018-05-11       Impact factor: 3.369

3.  International Phase III, Randomized, Double-Blind, Placebo and Active Controlled Study to Evaluate the Safety and Efficacy of Vibegron in Patients with Symptoms of Overactive Bladder: EMPOWUR.

Authors:  David Staskin; Jeffrey Frankel; Susann Varano; Denise Shortino; Rachael Jankowich; Paul N Mudd
Journal:  J Urol       Date:  2020-02-18       Impact factor: 7.450

4.  Vibegron 50 mg is the optimal algorithm in the pharmacologic management of overactive bladder: outcomes from a systematic review and meta-analysis.

Authors:  Zhongyu Jian; Chi Yuan; Hong Li; Wei Zhang; Kunjie Wang
Journal:  Int Urol Nephrol       Date:  2020-06-09       Impact factor: 2.370
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.